Quick Answer
Skye Bioscience, Inc. reported Net Income Loss of -$55.92 million for the year ending 2025.
- Skye Bioscience, Inc. showed a decrease of -110.5% in Net Income Loss from 2024 to 2025.
- This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$8.21 million | Q2 2018: -$2.66 million | Q3 2018: -$2.10 million | Q1 2019: -$14.77 million | Q2 2019: $15.91 million | Q3 2019: -$4.93 million | Q1 2020: -$2.34 million | Q2 2020: -$1.42 million | Q3 2020: -$1.30 million | Q1 2021: -$2.16 million | Q2 2021: -$2.02 million | Q3 2021: -$1.82 million | Q1 2022: -$3.04 million | Q2 2022: -$3.42 million | Q3 2022: -$3.13 million | Q1 2023: -$5.17 million | Q2 2023: -$3.11 million | Q3 2023: -$24.95 million | Q1 2024: -$5.02 million | Q2 2024: -$7.90 million | Q3 2024: -$3.90 million | Q1 2025: -$11.10 million | Q2 2025: -$17.62 million | Q3 2025: -$12.75 million.
- Over the full 15 years of available data (2012 to 2025), Skye Bioscience, Inc.'s Net Income Loss has declined by 1,240,393.1%.
- Historical annual values: Fiscal year 2025: -$55.92 million | Fiscal year 2024: -$26.57 million | Fiscal year 2023: -$37.64 million | Fiscal year 2022: -$19.48 million | Fiscal year 2021: -$8.52 million | Fiscal year 2020: -$6.56 million | Fiscal year 2019: $1.05 million | Fiscal year 2018: -$19.19 million | Fiscal year 2017: -$3.09 million | Fiscal year 2016: -$3.18 million | Fiscal year 2015: -$4.84 million | Fiscal year 2014: -$2.73 million | Fiscal year 2013: -$120.4 thousand | Fiscal year 2013: -$3.8 thousand | Fiscal year 2012: $4.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: